Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Personalis, Inc. (NASDAQ: PSNL) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Personalis’ financial performance, material agreements, reimbursement developments, and other events relevant to its precision oncology and medical laboratories business.
Form 8-K filings for Personalis frequently report material events such as quarterly and annual financial results, preliminary performance updates, and significant business milestones. Examples include 8-Ks furnishing press releases on results of operations and financial condition, and filings describing Medicare coverage determinations and reimbursement rates for the company’s ultrasensitive NeXT Personal MRD tests used in breast cancer recurrence surveillance.
Other 8-K filings detail material agreements, such as amendments to the commercialization and reference laboratory agreement with Tempus AI, Inc. Under that agreement, Tempus is authorized to market NeXT Personal in indications including breast cancer, lung cancer, immuno-oncology monitoring, and colorectal cancer, with specified exclusivity periods and standstill provisions. These filings help investors understand how Personalis structures partnerships around its tumor-informed MRD platform.
Through its periodic reports and current reports, Personalis discloses revenue composition across pharma tests and services, enterprise sales, population sequencing, clinical diagnostic revenue, and other categories, as well as information on cash, investments, and stockholders’ equity. Securities registration details in the filings confirm that Personalis’ common stock trades on The Nasdaq Global Market under the symbol PSNL.
On Stock Titan, SEC documents for PSNL are updated from EDGAR in near real time. AI-powered tools can summarize lengthy filings, highlight key items such as Medicare coverage changes, material agreements, and revenue breakdowns, and help users quickly locate information on topics like MRD reimbursement, commercialization partnerships, and capital structure without reading every page manually.
Personalis, Inc. provides advanced cancer genomic testing services used by physicians and drug developers for minimal residual disease detection, recurrence monitoring, and therapy selection. Key offerings include NeXT Personal Dx and NeXT Dx, supported by a CLIA-certified, CAP-accredited lab in Fremont, California.
The company recently secured Medicare coverage for NeXT Personal Dx in Stage II–III breast cancer (effective October 7, 2025) and Stage I–III non-small cell lung cancer (effective January 9, 2026), plus earlier coverage for its NeXT Dx comprehensive genomic profiling test. Despite this progress, Personalis reported a net loss of $81.3 million in 2025 and an accumulated deficit of $631.3 million, and remains dependent on a concentrated customer base, notably Moderna and the VA Million Veteran Program.
Personalis, Inc. reported fourth quarter and full year 2025 results and issued 2026 guidance, highlighting rapid growth in its clinical testing business alongside continued losses. Full year 2025 revenue was $69.6 million, down from $84.6 million, with a net loss of $81.3 million. However, clinical test volume surged nearly 400% to 16,233 tests, and Q4 clinical test revenue rose to $0.9 million from $0.2 million. The company ended 2025 with about $240 million in cash, cash equivalents and short-term investments, including $109 million of ATM proceeds. For 2026, Personalis guides to revenue of $78–$80 million, clinical revenue of $10–$11 million on 43,000–45,000 tests, and expects a net loss of about $105 million and cash usage of about $100 million as it invests behind 5x projected clinical revenue growth.
Personalis, Inc. executive Aaron Tachibana, the company’s CFO and COO, reported an acquisition of derivative securities through equity compensation. On February 23, he became entitled to 15,000 stock options at an exercise price of $0.00 per share, held as direct ownership.
According to the disclosure, this amount reflects the vesting of a performance stock option originally granted on March 15, 2024, after a specified reimbursement milestone was satisfied. The filing records this as a grant or award-type acquisition rather than an open-market purchase or sale of Personalis common stock.
Personalis, Inc. reported that Chief Medical Officer and EVP Richard Chen acquired 15,000 stock options through the vesting of a performance-based award. The options relate to a performance stock option originally granted on
Personalis, Inc. reported an insider equity transaction for Stephen Michael Moore, its SVP and Chief Legal Officer. He acquired 8,333 stock options, recorded as a grant or award at a reported price of
According to the footnote, this reflects the vesting of a performance stock option originally granted on
Personalis, Inc. reported that President and CEO Christopher M. Hall acquired rights to 33,333 shares through the vesting of a performance stock option. The option tranche vested on February 23, 2026 after the company met a specified reimbursement milestone tied to the original grant made on March 15, 2024.
The transaction is coded as a grant or award acquisition, with no cash paid per option at vesting. Following this vesting event, Hall holds 33,333 stock options related to this performance-based award as direct ownership.
Ameriprise Financial, Inc. filed a Schedule 13G reporting a significant ownership stake in Personalis, Inc. common stock. As of 12/31/2025, Ameriprise reports beneficial ownership of 6,287,151 shares, representing 7.1% of Personalis’ outstanding common stock.
Ameriprise reports no sole voting or dispositive power, with all reported voting and dispositive power shared across these holdings. The firm states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Personalis, and disclaims beneficial ownership of the shares reported.
Tempus AI, Inc., a 10% owner of Personalis, Inc., reported a series of open-market purchases of Personalis common stock. Between November 18 and December 22, 2025, Tempus AI bought multiple blocks of shares at weighted-average prices generally between $7.67 and $11.00, as detailed in the transaction table and footnotes.
After the latest reported trade on December 22, 2025, Tempus AI beneficially owned 13,039,067 shares of Personalis common stock, held directly. The footnotes explain that each reported price is a weighted average for numerous trades within stated intraday price ranges.
Personalis, Inc. investor Orin Hirschman and affiliated AIGH entities report a passive ownership position below 5% of the company’s common stock. The filing shows Mr. Hirschman beneficially owning 3,416,720 shares, representing 3.8% of the outstanding common stock, with sole voting and dispositive power.
AIGH Capital Management LLC separately reports beneficial ownership of 2,900,000 shares, or 3.3% of the class, also with sole voting and dispositive power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Personalis.
Personalis, Inc. insider trading report: Chief Financial Officer and Chief Operating Officer Aaron Tachibana exercised stock options for 1,201 shares of common stock at